MetaVia (MTVA) Expected to Post Quarterly Earnings on Thursday

Posted by Brian Himes on Aug 4th, 2026

MetaVia (NASDAQ:MTVA – Get Free Report) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.85) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

MetaVia (NASDAQ:MTVA – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). On average, analysts expect MetaVia to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MetaVia Price Performance

MetaVia stock opened at $1.48 on Tuesday. The firm has a market capitalization of $7.64 million, a P/E ratio of -0.29 and a beta of 0.95. The stock has a fifty day moving average price of $1.85 and a two-hundred day moving average price of $1.80. MetaVia has a 52-week low of $0.97 and a 52-week high of $19.03.

Hedge Funds Weigh In On MetaVia

A hedge fund recently bought a new position in MetaVia stock. Virtu Financial LLC purchased a new stake in shares of MetaVia Inc. (NASDAQ:MTVA – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent reporting period. 1.37% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on MTVA shares. Wall Street Zen raised shares of MetaVia to a “sell” rating in a report on Saturday, June 20th. HC Wainwright restated a “buy” rating on shares of MetaVia in a research report on Friday, July 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, MetaVia has a consensus rating of “Hold” and an average price target of $20.00.

Check Out Our Latest Stock Report on MTVA

MetaVia Company Profile

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.